INCYTE CORPORATION Other Nonoperating Income (Expense)
INCYTE CORPORATION (INCY) reported Other Nonoperating Income (Expense) of $2.77 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-28.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-04-28
- INCYTE CORPORATION other nonoperating income (expense) for the quarter ending 2026-03-31 was $2.77M, a 65.74% decline year-over-year.
- INCYTE CORPORATION other nonoperating income (expense) for the quarter ending 2025-12-31 was $5.66M, a 251.15% increase year-over-year.
- INCYTE CORPORATION other nonoperating income (expense) for the quarter ending 2025-09-30 was $4.04M, a 17.98% decline year-over-year.
- INCYTE CORPORATION other nonoperating income (expense) for the quarter ending 2025-06-30 was $7.31M, a 11.89% decline year-over-year.
- INCYTE CORPORATION other nonoperating income (expense) for fiscal 2025 was $25.11M, a 96.03% increase from fiscal 2024.
- INCYTE CORPORATION other nonoperating income (expense) for fiscal 2024 was $12.81M, a 8.07% decline from fiscal 2023.
- INCYTE CORPORATION other nonoperating income (expense) for fiscal 2023 was $13.93M.
- INCYTE CORPORATION other nonoperating income (expense) for fiscal 2022 was -$519.00K, a 104.87% decline from fiscal 2021.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 3 month as first filed | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 6 month as first filed | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 9 month as first filed | Other Nonoperating Income (Expense) 12 month | Other Nonoperating Income (Expense) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $2.77M 10-Q · filed 2026-04-28 | $8.44M derived: sum of 2 quarters · filed 2026-04-28 | $12.48M derived: sum of 3 quarters · filed 2026-04-28 | $19.79M derived: sum of 4 quarters · filed 2026-04-28 | ||||
| 2025-12-31 | $5.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $9.71M derived: sum of 2 quarters · filed 2026-02-10 | $17.01M derived: sum of 3 quarters · filed 2026-02-10 | $25.11M 10-K · filed 2026-02-10 | ||||
| 2025-09-30 | $4.04M 10-Q · filed 2025-10-28 | $11.35M derived: sum of 2 quarters · filed 2025-10-28 | $19.45M 10-Q · filed 2025-10-28 | $21.06M derived: sum of 4 quarters · filed 2026-04-28 | ||||
| 2025-06-30 | $7.31M 10-Q · filed 2025-07-29 | $15.40M 10-Q · filed 2025-07-29 | $17.02M derived: sum of 3 quarters · filed 2026-04-28 | $21.95M derived: sum of 4 quarters · filed 2026-04-28 | ||||
| 2025-03-31 | $8.10M 10-Q · filed 2026-04-28 | $9.71M derived: sum of 2 quarters · filed 2026-04-28 | $14.64M derived: sum of 3 quarters · filed 2026-04-28 | $22.93M derived: sum of 4 quarters · filed 2026-04-28 | ||||
| 2024-12-31 | $1.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $6.54M derived: sum of 2 quarters · filed 2026-02-10 | $14.84M derived: sum of 3 quarters · filed 2026-02-10 | $12.81M 10-K · filed 2026-02-10 | ||||
| 2024-09-30 | $4.93M 10-Q · filed 2025-10-28 | $24.20M 10-Q · filed 2024-10-29 | $13.22M derived: sum of 2 quarters · filed 2025-10-28 | $11.20M 10-Q · filed 2025-10-28 | $118.71M 10-Q · filed 2024-10-29 | -$96.78M derived: sum of 4 quarters · filed 2026-02-10 | ||
| 2024-06-30 | $8.29M 10-Q · filed 2025-07-29 | $49.77M 10-Q · filed 2024-07-30 | $6.27M 10-Q · filed 2025-07-29 | $94.51M 10-Q · filed 2024-07-30 | -$101.71M derived: sum of 3 quarters · filed 2026-02-10 | -$55.34M derived: sum of 4 quarters · filed 2026-02-10 | ||
| 2024-03-31 | -$2.03M 10-Q · filed 2025-04-29 | $44.74M 10-Q · filed 2024-04-30 | -$110.00M derived: sum of 2 quarters · filed 2026-02-10 | -$63.63M derived: sum of 3 quarters · filed 2026-02-10 | -$20.96M derived: sum of 4 quarters · filed 2026-02-10 | |||
| 2023-12-31 | -$107.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | -$61.61M derived: sum of 2 quarters · filed 2026-02-10 | -$18.94M derived: sum of 3 quarters · filed 2026-02-10 | $13.93M 10-K · filed 2026-02-10 | $172.35M 10-K · filed 2024-02-13 | |||
| 2023-09-30 | $46.37M 10-Q · filed 2024-10-29 | $89.04M derived: sum of 2 quarters · filed 2024-10-29 | $121.91M 10-Q · filed 2024-10-29 | $108.10M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-06-30 | $42.67M 10-Q · filed 2024-07-30 | $75.54M 10-Q · filed 2024-07-30 | $61.73M derived: sum of 3 quarters · filed 2025-02-10 | $73.24M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2023-03-31 | $32.87M 10-Q · filed 2024-04-30 | $19.06M derived: sum of 2 quarters · filed 2025-02-10 | $30.57M derived: sum of 3 quarters · filed 2025-02-10 | $31.09M derived: sum of 4 quarters · filed 2025-02-10 | ||||
| 2022-12-31 | -$13.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-10 | -$2.30M derived: sum of 2 quarters · filed 2025-02-10 | -$1.78M derived: sum of 3 quarters · filed 2025-02-10 | -$519.00K 10-K · filed 2025-02-10 | $39.93M 10-K · filed 2023-02-07 | |||
| 2022-09-30 | $11.51M 10-Q · filed 2023-10-31 | $12.04M derived: sum of 2 quarters · filed 2023-10-31 | $13.29M 10-Q · filed 2023-10-31 | $19.01M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-06-30 | $522.00K 10-Q · filed 2023-08-01 | $1.78M 10-Q · filed 2023-08-01 | $7.50M derived: sum of 3 quarters · filed 2024-02-13 | $9.45M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2022-03-31 | $1.26M 10-Q · filed 2023-05-02 | $6.98M derived: sum of 2 quarters · filed 2024-02-13 | $8.92M derived: sum of 3 quarters · filed 2024-02-13 | $13.31M derived: sum of 4 quarters · filed 2024-02-13 | ||||
| 2021-12-31 | $5.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $7.66M derived: sum of 2 quarters · filed 2024-02-13 | $12.05M derived: sum of 3 quarters · filed 2024-02-13 | $10.65M 10-K · filed 2024-02-13 | ||||
| 2021-09-30 | $1.95M 10-Q · filed 2022-11-01 | $6.34M derived: sum of 2 quarters · filed 2022-11-01 | $4.93M 10-Q · filed 2022-11-01 | $9.74M derived: sum of 4 quarters · filed 2023-02-07 | ||||
| 2021-06-30 | $4.39M 10-Q · filed 2022-08-02 | $2.98M 10-Q · filed 2022-08-02 | $7.79M derived: sum of 3 quarters · filed 2023-02-07 | $12.71M derived: sum of 4 quarters · filed 2023-02-07 | ||||
| 2021-03-31 | -$1.41M 10-Q · filed 2022-05-03 | $3.40M derived: sum of 2 quarters · filed 2023-02-07 | $8.32M derived: sum of 3 quarters · filed 2023-02-07 | $13.14M derived: sum of 4 quarters · filed 2023-02-07 | ||||
| 2020-12-31 | $4.81M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | $9.73M derived: sum of 2 quarters · filed 2023-02-07 | $14.54M derived: sum of 3 quarters · filed 2023-02-07 | $23.21M 10-K · filed 2023-02-07 | ||||
| 2020-09-30 | $4.92M 10-Q · filed 2021-11-02 | $9.73M derived: sum of 2 quarters · filed 2021-11-02 | $18.40M 10-Q · filed 2021-11-02 | $34.24M derived: sum of 4 quarters · filed 2022-02-08 | ||||
| 2020-06-30 | $4.82M 10-Q · filed 2021-08-03 | $13.48M 10-Q · filed 2021-08-03 | $29.33M derived: sum of 3 quarters · filed 2022-02-08 | $41.29M derived: sum of 4 quarters · filed 2022-02-08 | ||||
| 2020-03-31 | $8.66M 10-Q · filed 2021-05-04 | $24.51M derived: sum of 2 quarters · filed 2022-02-08 | $36.47M derived: sum of 3 quarters · filed 2022-02-08 | $51.47M derived: sum of 4 quarters · filed 2022-02-08 | ||||
| 2019-12-31 | $15.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-08 | $27.81M derived: sum of 2 quarters · filed 2022-02-08 | $42.81M derived: sum of 3 quarters · filed 2022-02-08 | $52.18M 10-K · filed 2022-02-08 | ||||
| 2019-09-30 | $11.96M 10-Q · filed 2020-11-05 | $26.96M derived: sum of 2 quarters · filed 2020-11-05 | $36.33M 10-Q · filed 2020-11-05 | $47.61M derived: sum of 4 quarters · filed 2021-02-09 | ||||
| 2019-06-30 | $15.00M 10-Q · filed 2020-08-04 | $24.37M 10-Q · filed 2020-08-04 | $35.65M derived: sum of 3 quarters · filed 2021-02-09 | $45.86M derived: sum of 4 quarters · filed 2021-02-09 | ||||
| 2019-03-31 | $9.37M 10-Q · filed 2020-05-05 | $20.65M derived: sum of 2 quarters · filed 2021-02-09 | $30.86M derived: sum of 3 quarters · filed 2021-02-09 | $36.67M derived: sum of 4 quarters · filed 2021-02-09 | ||||
| 2018-12-31 | $11.28M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-09 | $21.49M derived: sum of 2 quarters · filed 2021-02-09 | $27.30M derived: sum of 3 quarters · filed 2021-02-09 | $31.76M 10-K · filed 2021-02-09 | ||||
| 2018-09-30 | $10.21M 10-Q · filed 2019-10-29 | $16.02M derived: sum of 2 quarters · filed 2019-10-29 | $20.48M 10-Q · filed 2019-10-29 | $26.93M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-06-30 | $5.81M 10-Q · filed 2019-07-30 | $10.27M 10-Q · filed 2019-07-30 | $16.72M derived: sum of 3 quarters · filed 2020-02-13 | $22.21M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2018-03-31 | $4.46M 10-Q · filed 2019-04-30 | $10.91M derived: sum of 2 quarters · filed 2020-02-13 | $16.40M derived: sum of 3 quarters · filed 2020-02-13 | $20.47M derived: sum of 4 quarters · filed 2020-02-13 | ||||
| 2017-12-31 | $6.45M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $11.94M derived: sum of 2 quarters · filed 2020-02-13 | $16.01M derived: sum of 3 quarters · filed 2020-02-13 | $17.15M 10-K · filed 2020-02-13 | ||||
| 2017-09-30 | $5.49M 10-Q · filed 2018-10-30 | $9.56M derived: sum of 2 quarters · filed 2018-10-30 | $10.71M 10-Q · filed 2018-10-30 | |||||
| 2017-06-30 | $4.07M 10-Q · filed 2018-07-31 | $5.21M 10-Q · filed 2018-07-31 | ||||||
| 2017-03-31 | $1.15M 10-Q · filed 2018-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |